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Abstract
Background/Objectives The iron-binding affinity of vaginal lactoferrin (Lf) reduces iron available to genital pathogens. We
describe host reproductive, nutritional, infection and iron biomarker profiles affecting vaginal Lf concentration in young
nulliparous and primigravid women in Burkina Faso.
Subjects/Methods Vaginal eluates from women who had participated in a randomized, controlled periconceptional iron
supplementation trial were used to measure Lf using a competitive double-sandwich ELISA. For this analysis samples from
both trial arms were combined and pregnant and non-pregnant cohorts compared. Following randomization Lf was measured
after 18 months (end assessment) for women remaining non-pregnant, and at two antenatal visits for those becoming
pregnant. Associations between log Lf levels and demographic, anthropometric, infection and iron biomarker variables were
assessed using linear mixed models.
Results Lf samples were available for 712 non-pregnant women at end assessment and for 303 women seen at an antenatal
visit. Lf concentrations of pregnant women were comparable to those of non-pregnant, sexually active women. Lf con-
centration increased with mid-upper-arm circumference, (P= 0.047), body mass index (P= 0.018), Trichomonas vaginalis
(P < 0.001) infection, bacterial vaginosis (P < 0.001), serum C-reactive protein (P= 0.048) and microbiota community state
types III/IV. Adjusted Lf concentration was positively associated with serum hepcidin (P= 0.047), serum ferritin (P=
0.018) and total body iron stores (P= 0.042). There was evidence that some women maintained persistently high or low Lf
concentrations from before, and through, pregnancy.
Conclusion Lf concentrations increased with genital infection, higher BMI, MUAC, body iron stores and hepcidin, sug-
gesting nutritional and iron status influence homeostatic mechanisms controlling vaginal Lf responses.
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Introduction
An essential role of human lactoferrin (Lf) is to prevent
accumulation of free iron at mucosal sites. Lf demonstrates
a bacteriostatic effect related to its iron-binding affinity [1],
as well as antimicrobial activity that reduces bacterial
virulence [2], inhibitory effects on bacterial adhesion and
cell invasion, and ability to induce bacterial lysis [3, 4]. Lf
is expressed in the genital tract as part of the innate immune
system, active against common genital tract infections such
as Trichomonas (T) vaginalis, bacterial vaginosis (BV)-
related species, and Candida spp. Iron is an essential
nutrient for many genital tract bacteria [5], which have
developed specialized mechanisms for obtaining iron from
host tissues and extracellular fluid [6]. Iron is readily
available from heme during menses, while transferrin and
ferritin are transudated across the vagina lamina propria [7].
Lf concentrations rise with genital infection [8, 9] because
neutrophils release Lf from their secondary compartment to
sites of infection. Although Lf binds and reduces iron
availability, Lf-bound iron may itself become an iron source
for common bacteria such as Gardnerella vaginalis [10]. In
systemic infection, proteins involved in iron homeostasis
are regulated at the macrophage level during inflammation
[11] and the interaction between ferroportin and hepcidin
ensures that circulatory iron is related to host requirements.
A local hepcidin response to genital tract inflammation has
not been described. Independent of inflammation, Lf gene
expression is also regulated by estrogen, which controls Lf
produced constitutively in vaginal epithelial cells [3, 12].
Vaginal Lf concentrations vary over the menstrual cycle
with estrogen surges [13], and plasma Lf was reported to be
higher in pregnancy [14].
Given the lack of studies characterizing Lf profiles in
women of reproductive age, we sought to describe factors
affecting Lf concentration in a young, largely adolescent
population participating in a periconceptional trial to
investigate the safety of weekly iron supplementation in
rural Burkina Faso. Results of this randomized trial have
been reported [15, 16], including our finding of an effect
modifier of nutritional status for BV infection. The aims of
the present sub-study were (1) to measure and compare Lf
concentrations from vaginal eluates in nulliparae and pri-
migravidae; (2) to estimate the effects of participant char-
acteristics and nutritional status, measured by body mass
index (BMI) and mid-upper arm circumference (MUAC),
on vaginal Lf concentration; (3) to estimate the effects of
vaginal infections (BV, T. vaginalis, microbiota profiles),
and (4) to compare systemic iron and inflammation bio-
marker concentrations, body iron stores, and hepcidin levels
with vaginal Lf concentrations in order to determine if Lf, a
vaginal mucosal biomarker of infection, was associated
with systemic iron status and homeostasis.
Materials and methods
The main trial recruited young, healthy, nulliparous, non-
pregnant women aged 15–24 years from 30 rural villages
[17]. Adolescents (<20 years) comprised 93% of the sam-
ple. Human immunodeficiency virus prevalence is low
(<2%) [18]. After enrolment individuals were randomized
to receive either a capsule containing ferrous gluconate
(60 mg elemental iron) and folic acid (2.8 mg), or an iden-
tical capsule containing folic acid alone (2.8 mg), as
recommended by the World Health Organization, and
investigators and recipients were blinded to allocation [19].
Field workers dispensed supplements at weekly home visits,
and referred women with reported vaginal discharge or
generalized symptoms for free treatment at their nearest
Health Centre. Participants who became pregnant before the
end assessment at 18 months entered the pregnant cohort,
with the main trial outcomes determined at the first
antenatal visit (ANC1). Thereafter, weekly supplements
ceased and all pregnant women regardless of trial allocation
received routine daily antenatal iron supplementation
(60 mg elemental iron, 400 µg folic acid daily). In the pri-
mary trial analyses, weekly iron supplementation over an
18-month period did not significantly improve iron status,
probably because the iron was not absorbed due to the
effects of chronic malaria infection [15]; thus the two trial
arms are pooled for the analyses presented here.
All subjects gave written informed consent in accordance
with the Declaration of Helsinki. Individual and guardian
written consents for minors were obtained from all non-
pregnant women at recruitment with re-consent taken at entry
to the pregnancy cohort. The study protocol and subsequent
amendments were approved by the Liverpool School of
Tropical Medicine, UK, Research Ethics Committee (LSTM/
REC), the Institutional Review Board of the Institute of
Tropical Medicine, Antwerp, Belgium (IRB/ITM), the
Antwerp University Hospital Ethics Committee (EC/UZA),
the Institutional Ethics Committee of Centre Muraz (Comité
d’Ethique Institutionnel du Centre Muraz, CEI/CM); and the
National Ethics Committee (Comité Ethique pour la
Recherche en Santé, CERS) in Burkina Faso.
At enrolment demographic data were recorded and
height (nearest mm), weight (nearest 100 g), and MUAC
(mm) measured in duplicate. Lf, BV and T. vaginalis were
assessed after 18 months at the end assessment of non-
pregnant women and twice during pregnancy at an early/
late antenatal visit (ANC1/2). Women were requested to
provide self-taken vaginal samples using cotton-tipped
swabs that were returned to sterile, sealed tubes (Probact
Transport Swabs, Technical Services Consultants, Lancs,
UK) and kept cool until brought to the laboratory within
2–4 h. Samples were not requested during menses. Reported
discharge was recorded. One swab was used for a BV Gram
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stain and a second for measurement of vaginal pH (pH
indicator sticks ranged from 3.6–6.1), as previously
described [16]. Gram stains were scored using Nugent cri-
teria with 7–10 indicating BV, 4–6 intermediate, and 0–3
normal flora. Duplicate swabs were retained for preparation
of vaginal fluid eluates for Lf assays, microbiota and T.
vaginalis Polymerase Chain Reaction assays [16]. For
microbiota, bacterial profiling of the variable region 4 (V4)
of the 16 S rRNA gene was performed by NU-OMICS
(Northumbria University, UK) based on the Schloss wet-lab
MiSeq procedure [20].
Each tube containing a swab for vaginal eluate was
weighed before and after sampling and the weight difference
between initial and final weights was recorded. On laboratory
arrival 5 ml phosphate buffered saline was added to the tube
which was shaken for 5 min on high speed, before pipetting
and freezing at −20 °C. Lf concentration was measured by a
two-site enzyme-linked immunosorbent assay (double anti-
body sandwich ELISA) specific to human Lf (Kamiya Bio-
medical Co, KT-489, Seattle, US). The intra-assay coefficient
of variation was 9.7%. Duplicate samples were processed and
analyzed independently. The derived mean sample weight was
0.033 g, although weights were highly variable and 18% were
negative. Residuals from a linear regression of the difference
in estimated weights between the repeat samples against the
difference in Lf concentration suggested a sample weight
measurement error (standard deviation) of 0.035 g. Temporal
variation in derived weights suggested a batch or seasonal
effect and operator differences were not discerned. Mean Lf
values were therefore normalised by mean weight for type of
visit (allowing for pregnancy effects) derived from a linear
model which included month as a covariate. The denominators
used were ANC1: 0.038 g; ANC2: 0.048 g; end assessment:
0.038 g. A dilution series was used and values above the
ELISA assay range were assigned a nominal high value of
104 μg/ml, and those with no Lf detected were assumed to
have no fluid collected if the duplicate sample recorded a
detectable level.
Hemoglobin was measured (Sysmex automated analyser)
on fresh whole blood. Cut-off points for anaemia were
<12 g/dl for non-pregnant and <11 g/dl for pregnant
women. Methods for assessing iron biomarkers and C-
reactive protein (CRP) have been previously reported [21].
Briefly, plasma ferritin and transferrin receptor (sTfR) were
measured in duplicate by ELISA (Spectro Ferritin S-22 and
TFC 94 Transferrin Receptor, RAMCO Laboratories Inc,
Texas, US). CRP was assessed by ELISA (EU59131, IBL
International, GMBH, Hamburg, Germany) at the Nanoro
Research Laboratories, with an upper limit of the normal
range in non-pregnant individuals between 5 and 8 mg/l.
Iron deficiency was estimated using a ratio of sTfR µg/ml to
log10 ferritin >5.6 [21]. Body iron stores (BIS) (mg/kg) were
calculated using the equation derived by Cook et al. [22]
body iron (mg/kg)=−[log10 (1000 × sTfR/ferritin) –
2.8229]/0.1207, using adjusted ferritin based on an internal
regression correction approach allowing for inflammation as
described by Namaste et al. [23], based on all the trial data
[21]. Serum hepcidin was measured by competitive ELISA
assay as previously described [24].
Statistical analysis
No differences in vaginal infections [16] or Lf levels were
detected by study arm in the formal intention-to-treat ana-
lysis (Supplementary file Table 1), and trial arms were
pooled in all analyses presented here. Two primary analysis
datasets were constructed: (1) pregnant women with Lf
assessed at either ANC1 or ANC2 (303/315 with an ANC
visit); and (2) women who remained non-pregnant at end
assessment (712/819 of this cohort) (Fig. 1). Women with
uncertain pregnancy status at end assessment were excluded
from this data set. A subset of 53/73 women first identified
as pregnant at, or within 6 months, of end assessment were
screened again for Lf at ANC1 and ANC2 and are con-
sidered in a separate longitudinal analysis.
The contribution of each source of variation in Lf con-
centration was assessed using a linear random effects model
with terms for participant and visit (within participant), the
residual variance being that between the duplicate samples
taken at the same time from the same woman. Means of the
log(Lf) values derived from repeat samples collected at the
same visit were used for further analysis. The associations
between log(Lf) levels and demographic, anthropometric,
infection, and iron biomarker variables were assessed using a
linear mixed model, pooling all visits with a random effect
term to allow for correlations between levels in the same
individuals. A combined (non-pregnant and pregnant)
regression slope estimate was used. As nutritional status was a
priori identified as a potential confounder, a second model
was fitted which included MUAC, a surrogate for nutritional
73 in early 
pregnancy at or 
shortly aer end 
assessment survey
Baseline
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Pregnant
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Non-pregnant
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End assessment 
survey
972 aended
712 Lf assay
ANC1 assessment
315 aended
271 Lf assay
ANC2 assessment
247 aended
241 Lf assay
• 1224 Lf Assays in pregnant (ANC1 & ANC2) and non-pregnant 
women combined.
• 51 Lf assays available at end assessment, and ANC1 or ANC2 for 
longitudinal analysis.
303 pregnant 
women had Lf 
assays at either 
ANC1 or ANC2
Fig. 1 Flow diagram indicating non-pregnant and pregnant study
numbers and sample sizes for Lf assays
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status, as a covariate. Additional models considered interac-
tion terms between visit and the independent variable: as none
of these approached statistical significance (P > 0.05) they are
not considered further. Statistical analyses were conducted in
the R statistical environment version 3.3.1. [25].
Results
Lf samples were available for 712 non-pregnant women at
end assessment (after up to 18 months of weekly iron
supplementation) and for 303 women seen at ANC1 or
ANC2 who had become pregnant after randomization. Lf
assays were conducted for 271 at ANC1 and 241 at ANC2,
providing a total of 1224 samples for Lf assay (Fig. 1). At
ANC1 median and interquartile range (IQR) gestational age
was 18 (14–22) weeks and at ANC2, 34 (33–35) weeks.
Baseline characteristics of the non-pregnant and pregnant
women are shown in Table 1 for those with an Lf mea-
surement. Women who became pregnant were primi-
gravidae, older and more sexually active at baseline than
women who remained non-pregnant. At ANC1 prevalence
Table 1 Baseline characteristics
and follow-up iron biomarkers
in women who became pregnant
(at ANC1 or ANC2) or remained
non-pregnant (at end
assessment)
Variable1 Baseline Baseline
Became pregnant Remained non-pregnant
n= 303 n= 712
Demographics and medical history
Mean age at visit, years 17.0 (16.0–18.0) 16.0 (15.0–17.0)
Menarcheal at baseline (%) 282/303 (93.1) 544/712 (76.4)
Mean reproductive age (if menarcheal), years 3.0 (2.0–4.0) [1 missing] 3.0 (2.0–4.0)
Education (%) No schooling 199/302 (65.9) 377/709 (53.2)
Primary 55/303 (18.2) 166/712 (23.3)
Lower/higher secondary 48/302 (15.9) 166/709 (23.4)
Drinks alcohol (%) 166/303 (54.8) 258/712 (36.2)
Sexually active (%) 113/303 (37.3) 97/711 (13.6)
Anthropometry
Mean MUAC, cm 24.0 (22.7–25.2) 23.0 (21.7–24.5)
MUAC < 21 cm 16/303 (5.3) 107/712 (15.0)
Mean BMI, kg/m2 20.0 (18.8–21.0) 19.1 (17.8–20.4)
BMI < 18.5 kg/m2 61/303 (20.1) 262/712 (36.8)
Anaemia and iron biomarkers ANC12 End assessment3
Pregnant Hb < 11 g/dl; non-pregnant Hb <
12 g/dl
209/303 (69.0) 307/709 (43.3)
Mean ferritin, µg/l 97.0 (50.2–175.8) [1
missing]
52.0 (28.0–91.5) [4
missing]
Mean adjusted ferritin, µg/l4 46.9 (26.4–88.1) [1 missing] 37.2 (18.8–65.1) [4
missing]
Mean sTfR, µg/ml 3.0 (2.3–4.1) [2 missing] 3.7 (2.8–5.2) [6 missing]
Ratio sTfR(µg/ml)/log10 ferritin(µg/l) > 5.6,
(%)5
34/301 (11.3) 143/706 (20.3)
Mean ZPP, µmol/mol heme 102 (87–120) [24 missing] 93 (78–115) [2 missing]
Mean body iron stores, mg/kg4 5.9 (3.8–8.6) [2 missing] 5.1 (2.3–7.4) [6 missing]
Mean hepcidin, µmol/ml 3.3 (1.1–7.8) [4 missing] 3.2 (1.3–6.2 [6 missing]
Mean CRP, mg/l 4.4 (1.2–13.0) [3 missing] 0.6 (0.2–1.5) [5 missing]
MUAC mid-upper arm circumference, BMI body mass index, sTfR serum transferrin receptor, CRP C-
reactive protein, ANC antenatal clinic visit, Hb hemoglobin
1Brackets: interquartile range, or %
2Includes pregnancies identified at, or shortly after, end assessment
3Menarcheal n= 621; non-menarcheal n= 91
4Ferritin estimated using an internal regression correction approach allowing for inflammation based on CRP
as described by Namaste et al. [23]
5Ratio sTfR/log10 ferritin provides the estimate of proportion iron deficient [21]
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of iron deficiency was 11.3% in pregnant women, and at
end assessment 20.3% in non-pregnant women.
Mean Lf concentration for pregnant women was 806
(65–4386) µg/ml (n= 271) and for non-pregnant 201
(66–936) µg/ml (n= 712). Lf distributions are shown in
Supplementary file, Fig. S1. Lf concentration did not differ
by menarcheal status; therefore both menarcheal groups
were pooled in further analyses of the non-pregnant cohort
(Supplementary file, Fig. S2). Pregnant women had higher
Lf levels (difference in log10 Lf= 0.45, 95% CI, 0.33–0.57,
P < 0.0001) than non-pregnant women. Concentrations did
not differ between ANC1 and ANC2 (Supplementary file,
Fig. S2). Mean Lf concentration in pregnancy was similar to
that of sexually active non-pregnant women and was inde-
pendent of gestation (Fig. 2).
There was large variation in log10 Lf values between
individuals ranging over six orders of magnitude. The
within patient/visit estimated assay SD in log10 Lf was 0.47
and the interclass correlation coefficient for replicate mea-
surements was 0.90, indicating 90% of variation was due to
true differences between women or visits. The between-visit
(within woman) variation SD was 0.65, and the between-
women SD was 0.75, giving a total SD between indepen-
dent assessments of 1.00. The within-patient ICC was 0.57,
indicating that Lf values were strongly correlated over time,
with individuals having levels that persisted. This is illu-
strated in Fig. 3, which shows the longitudinal trends in Lf
concentration for the 51 women assessed at end assessment
and who were identified by urine screening at that time as in
very early pregnancy and then who later provided additional
samples as part of the pregnant cohort at ANC1 and/or
ANC2.
Some 37% of non-pregnant women had a baseline BMI
< 18.5 kg/m2 (Table 1). Across both pregnant and non-
pregnant women, Lf concentrations increased with MUAC
(P= 0.047) and BMI (P= 0.018), (Table 2). The effect of
sexual activity on Lf concentration in non-pregnant women
remained after adjusting for MUAC (P= 0.005) (Table 2).
There was no Lf association with calendar age or repro-
ductive age.
Prevalence of BV was 11% and T. vaginalis 4% at the
non-pregnant end assessment, and 7% and 13%, respec-
tively, at ANC1. Lf concentration by infection category is
shown in Supplementary Fig. S3. Lf levels were 6.6-fold
higher in all women with BV (difference in log10 Lf= 0.82,
0.63–1.00, P < 0.001), 11.5-fold higher with T. vaginalis
(difference in log10 Lf= 1.06, 0.85–1.26, P < 0.001), and
1.8-fold higher with vaginal discharge (difference in log10
Fig. 2 Lf concentration (μg/ml) by gestation and in non-pregnant and
sexually active women. Gestation determined by ultrasound at ANC1
in the pregnant cohort. Mean with 95% CI for each lunar month of
gestation plus values for the non-pregnant group (Non-pregnant) and
the subset of non-pregnant women who were known to be sexually
active at the baseline assessment. The horizontal green line indicates
non-pregnant mean; blue line indicates linear regression line of log
(Lf) v gestation with a random effect to allow for correlations within
participants. The slope is non-significant, P= 0.14
Fig. 3 Longitudinal Lf
concentration (μg/ml) in 51
women seen while non-pregnant
(at end assessment) and while
pregnant (at ANC1 and/or
ANC2). Lines join the
measurements on the same
woman at the three time points.
Panels and colors indicate the
non-pregnant Lf quartile: low,
intermediate and high levels at
the first assessment time. Closed
circle: BV or T. vaginalis
infection at the time of visit;
open circle: no infection. Data
are offset slightly for clarity.
Shaded boxplots are included,
showing the full cohort range
(median, IQR, min, max)
Mucosal lactoferrin response to genital tract infections is associated with iron and nutritional. . .
Lf= 0.26, 0.07–0.45, P= 0.006) (Table 2). Receiving an
antifungal prescription, predominantly for a vaginal infec-
tion, during the 6 months prior to assessment, was asso-
ciated with higher Lf values (< 0.001). Antibiotic
prescriptions, mainly for respiratory, gastrointestinal and
localized infections, showed a borderline significant asso-
ciation (P= 0.066). Infection associations with Lf did not
differ significantly after adjusting for MUAC.
Three microbiota vaginal CSTs were matched: CST I
(40.4%), III (25.8%) and IV (33.8%), dominated, respec-
tively, by Lactobacillus (L) crispatus, L. iners and a mixed
community with reduced lactobacilli. The 15 bacterial
genera associated with each CST category are shown in Fig.
4. Log Lf concentration differences for CST III and IV
compared to CST 1 were 0.59, 0.46–0.73, and 0.58,
0.46–0.71, respectively (P < 0.001) (Supplementary file,
Fig. S4).
There were significant positive trends towards increasing
Lf concentration, adjusted for visit and MUAC, with serum
ferritin (P= 0.018), serum hepcidin (P= 0.047) and total
BIS (P= 0.042), with a borderline association with serum
CRP concentration (P= 0.048) (Table 2). ZPP and sTfR
adjusted for MUAC were not significantly associated with
Lf concentration.
Discussion
Both nutritional and iron biomarker correlates with Lf
concentration were identified in this analysis. The higher Lf
in pregnancy probably relates to exposure to sexually
transmitted infections such as T. vaginalis consequent to
regular sexual activity, as well as to higher estrogen levels
[26]. No standardized methodology is available for
Table 2 Effect estimates of
demographic, anthropometric,
infection, and iron biomarkers
with vaginal Lf concentration
Adjusted for visit1 Adjusted for visit and MUAC2
Parameter N3 Pvisit
4 Effect (95%CI) P5 Pvisit
4 Effect (95%CI) P5
Reproductive age (per year) 1188 <0.001 0.01 (−0.02–0.05) 0.40 <0.001 0.01 (−0.03–0.04) 0.67
Sexually active6 (yes) 711 NA 0.28 (0.08−0.48) 0.005 NA 0.24 (0.04–0.44) 0.019
Alcohol (yes) 1212 <0.001 −0.02 (−0.14–0.09) 0.71 <0.001 −0.01 (−0.13–0.10) 0.81
BMI (per kg/m2) 1224 <0.001 0.03 (0.01–0.06) 0.018 NA NA NA
MUAC (per cm) 1224 <0.001 0.03 (0.00–0.06) 0.047 NA NA NA
No schooling (yes) 1219 <0.001 −0.01 (−0.13–0.11) 0.83 <0.001 −0.01 (−0.12–0.0) 0.93
Nugent scores: 0–3 1146 <0.001 Reference <0.001 <0.001 Reference <0.001
4–6 NA NA 0.41 (0.23–0.59) NA <0.001 0.42 (0.24–0.60) NA
7–10 NA NA 0.82 (0.63–1.00) NA <0.001 0.81 (0.62–1.00) NA
T. vaginalis (yes) 1215 <0.001 1.06 (0.85–1.26) <0.001 <0.001 1.06 (0.86–1.26) <0.001
Vaginal discharge (yes) 1221 <0.001 0.26 (0.07–0.45) 0.006 <0.001 0.26 (0.08–0.45) 0.006
Antibiotic use (yes) 1224 <0.001 0.12 (−0.01–0.24) 0.066 <0.001 0.11 (−0.01–0.24) 0.075
Antifungal use (yes) 1224 <0.001 0.49 (0.25–0.73) <0.001 <0.001 0.48 (0.24–0.72) <0.001
Adjusted ferritin, µg/l7 1216 <0.001 0.07 (0.01–0.13) 0.021 <0.001 0.07 (0.01–0.13) 0.018
sTfR, µg/ml 1216 <0.001 −0.01 (−0.15–0.13) 0.86 <0.001 0.00 (−0.14–0.14) 0.99
ZPP, µmol/mol heme 1216 <0.001 −0.03 (−0.18–0.12) 0.73 <0.001 −0.02 (−0.17–0.13) 0.82
Ratio sTfR (µg/ml) /log10 ferritin (µg/l) 1213 <0.001 −0.08 (−0.18–0.02) 0.14 <0.001 −0.07 (−0.18–0.03) 0.16
Hepcidin, µmol/ml 1211 <0.001 0.05 (0.00 0.09) 0.040 <0.001 0.04 (0.00–0.09) 0.047
CRP, mg/l 1212 <0.001 0.03 (0.00–0.07) 0.062 <0.001 0.04 (0.00–0.07) 0.048
Hb, g/dl 1219 <0.001 −0.01 (−0.45–0.43) 0.96 <0.001 −0.06 (−0.49–0.38) 0.81
Body iron stores, mg/kg7 1213 <0.001 0.014 (0.001–0.028) 0.041 <0.001 0.014 (0.000–0.028) 0.042
BMI body mass index, MUAC mid-upper-arm-circumference, sTfR serum transferrin receptor,
ZPP whole blood zinc protoporphyrin, CRP C-reactive protein, NA not applicable
1Combined data for Lf measurements at follow-up in non-pregnant (end assessment) or pregnant women
(ANC1 and ANC2). Effect sizes are differences in Log10 Lf per unit, or between groups, adjusting for visit,
or visit and MUAC, as fixed factors, and participant as a random effect in a linear mixed model that includes
all women and visits in a single analysis
2Additional model adjusted also for MUAC assessed at ANC1 or end assessment
3Number of Lf measurements included in the analysis across all visits after missing data excluded
4Pvisit: P-value associated with the visit effect
5Significance of the effect of the variable itself—average across all visits
6Assessed at baseline and related to Lf concentration measured for non-pregnant women at end
assessment only
7Ferritin estimated using an internal regression correction approach allowing for inflammation based on CRP
as described by Namaste et al. [23]
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measuring Lf in vaginal fluid and no pre-determined cut-
offs are available to denote high and low values [27, 28].
For specimen collection, self-taken swabs were acceptable
to the participants. Although swabs/tubes were weighed to
allow adjustment for the volume of vaginal fluid sampled,
this did not account for all variation between mean weights,
which could be affected by hydration and seasonal effects.
Normalization therefore used mean rather than individual
sample weights. Despite this the assay was sufficiently
sensitive to detect differences associated with participant
and clinical characteristics. Lf concentrations showed a
wide range in values but longitudinal profiling and analysis
of the components of variation indicated women with per-
sistently high or low Lf concentrations, maintained from
before, and through, pregnancy. They may represent hyper-
or hypo-responsive cohorts since BV and T. vaginalis
infections were identified in both categories (Fig. 3).
Infection was the main factor affecting Lf concentration, but
it remains unclear whether these higher Lf concentrations
are helpful or detrimental. Lf is known to be a potent
inhibitor of Candida albicans [29] and synergistically
enhances the effects of the azole class of antifungal agents
[30]. We report higher Lf concentrations in CSTs III/IV,
conditions in which healthy lactobacilli are generally
reduced but L. Iners survives. Unlike other lactobacilli, L.
iners requires iron for growth. It probably utilizes iron
released from erythrocyte destruction by Gardnerella
vaginalis and flourishes during menses [31]. Its role in
maintenance of iron homeostasis during infection warrants
further research.
Adjustments were made for nutritional status using
MUAC, which unlike BMI does not change with gestation
in normal pregnancies, and mean MUAC was comparable
for non-pregnant and pregnant women. Nutritional status is
important for mucosal immunity, which may be affected by
states of under- or over-nutrition. Serum Lf concentration
positively correlates with insulin resistance in obese women
[32]. Leptin, an adipocytokine produced by epithelial cells
and adipose tissue, has a role in mucosal defenses possibly
mediated by expression of IL23 [33]. The significant posi-
tive association of BMI and MUAC with vaginal Lf is
consistent with leptin's influence on constitutive Lf pro-
duction in young women who are still maturing.
We have shown a positive association between serum
hepcidin and vaginal Lf concentration. These results may
indicate a simple association of inflammation with these
markers, but increased hepcidin would still impact on iron
homeostasis. Hepcidin is produced by hepatocytes, but may
also be locally synthesized by myeloid cells in response to
pathogens, and has been observed in neutrophils migrating
to tissue sites of infection [34]. There are few prior reports
on hepcidin response following local, as opposed to sys-
temic infection other than in the gastro-intestinal tract dur-
ing colitis [35], and in viral keratitis [36]. The mechanisms
are unclear but in vivo studies implicate host induction of
local acute-phase response proteins and evidence of a host-
imposed metal ion limited environment [37]. Hepcidin
expression is inhibited in states of iron deficiency. Host
nutritional and iron status may influence the homeostatic
mechanisms controlling vaginal Lf expression. Vaginal Lf
concentrations were increased in better-nourished women,
yet we have previously reported that, at baseline, women
who were iron deficient were more likely to have normal
vaginal flora [16]. In conclusion, Lf concentrations
increased with genital infection, higher BMI, MUAC, BIS
and hepcidin, suggesting nutritional and iron status influ-
ence homeostatic mechanisms controlling vaginal Lf
responses. Further research is needed to elucidate whether
Fig. 4 Taxonomic abundance plots of bacteria associated with CST I,
III and IV. Boxplots show the 15 genera most associated with CST
differences and are plotted in order of significance. The centre line
denotes the median, the boxes cover the 25th and 75th percentiles, and
the whiskers extend to the most extreme data point, which is no more
than 1.5 times the length of the box away from the box. Points outside
the whiskers represent outlier samples. Statistical comparisons based
on the Kruskal-Wallis test and all P-values are adjusted for multiple
comparisons using the false discovery rate algorithm, where ***
denotes FDR P < 0.001
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genital infections induce a hepcidin response, which could
influence iron availability to vaginal bacteria and fungi.
Figure S5 in Supplementary file 2 outlines potential path-
ways that could be explored.
Supplementary material
Supplementary file 1 (word doc.) includes the intention to
treat comparison of Lf by trial arm. Four supplementary
figures provide data on 1) Fig. S1. Lf distribution curves; 2)
Fig. S2. Non-significant Lf differences for menarche/ANC
visit 3); Fig. S3. Boxplots of Lf for six infection indicators;
4) Fig. S4. Lf in three CST by study visit.
Supplementary file 2 provides a diagram and brief
description of potential systemic or local hepcidin effects
with genital infection. This schema is not deduced from
study results but relates to discussion points speculating on
the role of hepcidin at this mucosal site.
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